Now ethical clearance is on its way and we dose first human. But the progression of phase 1 in line with Walter Reed results 1 month later puts the company in poll position to access the 20 million in non dilutive funding phase 2. Good news flow ahead setting up the company
Ann: NYR Completes Safety Studies Ahead of Phase I Clinical Trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.015(4.29%) |
Mkt cap ! $70.65M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 31.0¢ | $164.7K | 498.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64497 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 7480 | 1 |
View Market Depth
| Last trade - 12.44pm 23/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |